Category Archives: Dual/triple agonist

Cellectis to Provide Updates of All Clinical Programs in 2023; Company to Advance FAP-Targeting UCART Program in Solid Tumors into the Clinic; Precision Actively Seeking Partners to Advance Azer-cel and PBCAR19B; Cellectis’s and Precision’s Q2 2023 Earnings Call Summary

On Friday, August 4, Cellectis held its Q2 2023 earnings call (press release) highlighting anticipated updates for the clinical programs of UCART22 (allogeneic CD22 CAR-T), UCART20x22 (allogeneic CD20xCD22 CAR-T) and UCART123 (allogeneic CD123 CAR-T) later in 2023. On the same day, Precision reported its Q2 2023 earnings call (press release) reiterating the receipt of final Type B meeting minutes from the FDA providing clarity on the potential registrational pathway of its lead asset azer-cel (PBCAR0191; allogeneic CD19 CAR-T), and the active discussions with potential partners for the development of its cell therapy assets. Below, Celltelligence provides insights on Cellectis’s updates of its UCAR-T assets, while discussing Precision’s active search for partnerships and azer-cel’s potential in LBCL.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

GC012F Results in MM and NHL to Be Presented at ASCO and EHA; New GC012F Trial in SLE; GC007g Demonstrates Remarkable Ph1 IIT Results in ALL; Gracell’s Q1 2023 Earnings Call Summary

On Monday, May 15, Gracell held its Q1 2023 earnings call (press release) highlighting the presentation of results from GC012F (BCMA x CD19 FasTCAR-T) and GC007g (allogeneic CD19 CAR-T) in several hematological indications at ASCO and EHA 2023, while disclosing the initiation of a Ph1 IIT evaluating GC012F in refractory systemic lupus erythematosus (SLE). Below, Celltelligence provides insights on the interest of Gracell in establishing a collaboration for the development of the GC012F’s Ph1b/2 trial for ≥4L MM to be initiated in the US, while comparing GC012F to its main competitors in the SLE field.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Arcellx’s CART-ddBCMA Program to Be Expanded; Precision to Provide Clinical Updates on Azer-cel and PBCAR19B Programs in May 2023; Arcellx’s and Precision’s Q1 2023 Results Summary

On Monday, May 8, Arcellx released its Q1 2023 results (press release) highlighting the progress made in the clinical development of its lead asset CART-ddBCMA (autologous BCMA CAR-T) for ≥4L MM. A day later, Precision reported a business update (press release) confirming that clinical updates for its allogeneic CD19 CAR-Ts (azer-cel and PBCAR19B) in NHL patients are still anticipated in May 2023. Below, Celltelligence provides insights on the potential expansion of the CART-ddBCMA’s iMMagine program with a future iMMagine-3 trial while commenting on the expected clinical updates of Precision’s cell therapy assets.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

GC012F’s Ph1/2 Trials in the US and China to Initiate in 2023; Will FasTCAR-Ts be as Fast as Initially Thought? Gracell’s Q4 2022 Earnings Call Summary

On Monday, March 13, Gracell held their Q4 and FY 2022 earnings call (press release / presentation) highlighting the upcoming initiation of GC012F’s (autologous BCMA x CD19 FasTCAR-T) Ph1/2 trials for r/r MM in the US and China. Additionally, management reported clinical updates for GC007g (allogeneic CD19 CAR-T) and GC506 (CLDN18.2 SMART CAR-T). Below, Celltelligence provides insights on Gracell’s potential partnership for advancing the clinical development of GC012F in the US, while discussing if fast manufacturing platforms will ultimately be able to differentiate themselves from traditional autologous CAR-Ts.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Gracell’s GC012F IND Submission Plans; Ph2 Portion of GC007 Trial to Start in Q3 2022; Gracell’s Q2 2022 Earnings Call Summary

On Monday, August 15, Gracell held their Q2 2022 earnings call (press release / presentation) highlighting GC012F’s (autologous BCMAxCD19 FasTCAR-T) IND filing plans both in the US and China, while updating clinical milestones for both TruUCAR and SMART CAR-T platforms. Below, Celltelligence provides insights on regulatory updates for GC012F in r/r MM and the potential delay in the GC027 trial (allogeneic CD7 TruUCAR-T) for r/r T-ALL patients.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Yescarta and Kymriah Product Attributes; Early Results from Gracell’s GC502 Ph1 Study in r/r B-ALL; Legend’s LB1901 Ph1 Study Design in r/r TCL; AACR 2022 Analysis 3

AACR 2022 Analysis 3: Several clinical updates were presented by Gilead, Novartis, Gracell, and Legend. Below, Celltelligence provides insights and context for each presentation. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

How Engineered CAR-NK Cells Could Overcome Several Major Challenges Faced by CAR-Ts; Nkarta and CRISPR Tx Report Preclinical Data for Developing a CD70 CAR-NK and a NK:T Treatment; AACR 2022 Analysis 1

AACR 2022 Analysis 1: Several preclinical and clinical updates were presented describing potential strategies to overcome key hurdles associated with NK-based cell therapies. Below, Celltelligence provides insights and context for each presentation. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Cilta-cel Demonstrates Improved Efficacy in Matched Analyses vs SoC; Cilta-cel’s New CARTITUDE-5 Trial in NDMM; Anakinra Prophylaxis Fails to Improve Orva-cel’s Safety Profile; Initial Clinical Data from Celyad’s CYAD-211 BCMA CAR-T; Gracell’s Investor Event: Will MRD Negativity Become a New Surrogate Marker? Updated Clinical Data from IASO’s CT103A; EHA 2021 Day 2

On the second day of EHA 2021, six key clinical updates were presented from JNJ / Legend, BMS, Celyad, Gracell, and IASO Biotherapeutics. Of note, Celyad and Gracell held two EHA-related investor events, while a new clinical trial for cilta-cel was observed on CT.gov. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Results from Kymriah’s Ph2 ELARA Trial; When Could Kymriah Become Approved in FL? Is Retreatment With Yescarta Commercially Feasible? CBMG Highlights Results From C-CAR066 and C-CAR039; ASCO 2021 Day 3 Part II

On the third day of ASCO 2021, five key clinical updates were presented from Novartis, Gilead, and CBMG. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

ACGT Summit Round-Up: Strategies to Overcome the Challenges of Solid Tumor Targeting

During the Alliance for Cancer Gene Therapy (ACGT) Summit 2021 on April 29, three key cell therapy related topics were discussed to overcome the challenges associated with the solid tumor microenvironment (TME):

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.